Evaluating Arnica Tincture Versus Intralesional Pentavalent Antimonials for Safe and Effective Treatment of Localized Cutaneous Leishmaniasis in Patients Aged 12 and Older

What this Trial Is About

Researchers are evaluating the safety and effectiveness of arnica tincture as a topical treatment for localized cutaneous leishmaniasis CL, a parasitic skin disease caused by Leishmania species. The study compares arnica tincture to the current local treatment with intralesional pentavalent antimonials. This trial builds on prior research showing positive results for arnica tincture in Colombia and aims to offer a potentially safer option with fewer systemic side effects. This is a randomized, single-blind clinical trial including two treatment groups. One group will apply arnica tincture topically three times a day for 30 days, while the other will receive intralesional injections of pentavalent antimonials once weekly for five weeks, dosed by lesion size. Both treatments target localized skin lesions caused by CL, and the study evaluates the safety and healing outcomes of these approaches. Participants will be assessed through clinical examinations of their lesions at regular intervals up to 90 days post-treatment to measure healing rates. Safety will be monitored by recording adverse effects. Follow-up visits will continue for more than three months to observe final healing status and any treatment-related issues. The trial aims to provide data on both effectiveness and side effects to inform future treatment choices for CL patients.

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.